Sign in
WithdrawnNo phase

Effects of Pressure-controlled Intermittent Coronary Sinus Occlusion (PiCSO) Therapy on miRNAs Expression and Absolute Microvascular Resistance by Continuous Thermodilution in ST-segment Elevation Myocardial Infarction (STEMI) Patients: PiCSO-STEMI TRIAL

Key facts

Who runs it
Fundacio Privada Mon Clinic Barcelona
Trial code
Status
Withdrawn
Started
14 Nov 2022
Ended
21 Jun 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • PiCSO Impulse System
  • Percutaneous Coronary Intervention (PCI)
Record updated
14 August 2025
Why it stopped
Lack of financial support for recruitment and follow-up activities.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • Age ≥ 18 years old
  • Anterior STEMI (ECG with persistent elevation ≥ 2 mm (0.2 mV) in 2 or more contiguous anterior precordial leads (V2, V3, V4) in men or ≥ 1.5 mm (0.15 mV) in women
  • Culprit lesion in proximal or mid Left Anterior Descending Artery (LAD)
  • Pre-PCI TIMI flow 0-1
  • Symptoms consistent with myocardial ischemia (persistent chest pain, dyspnea, nauseas/vomiting, fatigue, palpitations or syncope) present for ≤ 12 hours
  • The patient is eligible for primary PCI
  • Informed consent received and signed for study enrollment

Who cannot take part

  • Implants or foreign bodies in the coronary sinus
  • Previous MI or Coronary Artery Bypass Graft (CABG)
  • Previous history of stroke, transient ischemic attack (TIA) or reversible ischemic neurological deficit within last 6 months
  • Active participation in another drug or device investigational trial
  • Patients with definite or probable coronavirus disease 19 diagnosis within 2 weeks prior to STEMI
  • Known allergies to polyurethanes, Polyethylene Terephthalate (PET) or stainless steel
  • Known large pericardial effusion or cardiac tamponade
  • Cardiopulmonary resuscitated (CPR) cardiac arrest ≥ 5 minutes whom baseline neurologic status is not present
  • Known contraindication for adenosine administration (severe asthma, complicated Atrioventricular (AV) block, critical aortic stenosis, severe cardiac arrhythmias, severe valve diseases)
  • Medical, social or psychological condition that limits the ability of patient to participate in the study
  • Known severe kidney disease (eGFR <=30 mL/min/1.73) and/or hemodialysis
  • Contraindication to coronary angiogram or PCI
  • Known pregnancy or breastfeeding
  • Known coagulopathy
  • Central hemodynamically relevant left-right shunt
  • Unconscious at presentation
  • Need for circulatory support
  • Need for invasive mechanical ventilation
  • Need for temporal intravenous pacemaker
  • Patient not suitable for femoral access
  • Known epicardial stenosis greater than 50% distal to the culprit LAD lesion

About the trial

What the trial wants to find out

In this study we pretend to determine the molecular (miRNAs expression, angiogenic and inflammatory biomarkers) and microcirculatory (assessed by the innovative continuous intracoronary thermodilution technique) effects of PiCSO compared to a standard PCI control group in patients with high-risk anterior STEMI. Then, we aim to assess the efficacy of these molecular biomarkers as prognostic tools. Also, we will evaluate the impact of PiCSO on the coronary microcirculation beyond the acute phase in the follow-up six months after STEMI. Finally, we will assess PiCSO influence on Heart Failure (HF) clinical variables and patients' quality of life including a cost-effectiveness assessment in the mid-term follow-up one year after the STEMI event.

The 2 groups in the trial

  • PICSO+PCITreatment being tested

    Treatment: PiCSO Impulse System and Percutaneous Coronary Intervention (PCI)

  • Standard PCIExisting treatment, for comparison

    Treatment: Percutaneous Coronary Intervention (PCI)

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
14 August 2025